Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Raritan, New Jersey 08869


Purpose:

To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.


Criteria:

Inclusion Criteria Patients must have the following: HIV infection. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Active opportunistic infection or neoplasm. - High likelihood of death during study. - Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease. - Donation of > 1 unit blood or acute loss of blood within one month of study entry. Patients with the following prior conditions are excluded: - History of opportunistic infection. - Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone. Prior Medication: Excluded: Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.


NCT ID:

NCT00002249


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Raritan, New Jersey 08869
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 23, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.